Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by bionicjoeon Mar 23, 2019 11:41am
112 Views
Post# 29526919

RE:4 million for the till

RE:4 million for the till
floatinketucky wrote: 10,538,599______$0.375______$03,951,975____06-Nov-21

Just needs price support. 

Theralase Researchers Receive Government Grant /June 28, 2018https://www.fscwire.com/newsrelease/theralase-researchers-receive-government-grant

Preliminary Shelf Prospectus (NI 44-102) dated July 30, 2018 Closed on December 18, 2018  





Just to be clear for the newbies to this SH site, Theralase the company did not receive a dime from the federal grant and actually contributed its services to those researchers who btw don't work exclusively for TLT. As for the closing of the Shelf Prospectus, the announcement was made on Sedar by the OSC with no clarification given by Theralase in the 3 months that have passed why the action was taken.

All kinds of warrant cashing figures have been thrown around on this board. I suggest we wait for the MD&A which will upon us soon for the official numbers. SH posters have been wrong in the past. The bottom line is how much money is needed to fulfill their phase 2 obligations along with having enough cash to pay for the day to day expenses of 2 divisions. This will be the first chance to see the new CEOs in action. Let's see how they handle themselves.

Bullboard Posts